Healthcare - Biotechnology - NASDAQ - US
$ 0.744
-3.7 %
$ 85.7 M
Market Cap
-8.27
P/E
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc.[ Read More ]
The intrinsic value of one CHRS stock under the base case scenario is HIDDEN Compared to the current market price of 0.744 USD, Coherus BioSciences, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart CHRS
FINANCIALS
257 M
REVENUE
-203 M
OPERATING INCOME
-238 M
NET INCOME
-175 M
OPERATING CASH FLOW
145 M
INVESTING CASH FLOW
69.6 M
FINANCING CASH FLOW
70.8 M
REVENUE
-6.39 M
OPERATING INCOME
-10.8 M
NET INCOME
-62 M
OPERATING CASH FLOW
444 K
INVESTING CASH FLOW
-167 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Coherus BioSciences, Inc.
| Current Assets | 476 M |
| Cash & Short-Term Investments | 118 M |
| Receivables | 261 M |
| Other Current Assets | 97.4 M |
| Non-Current Assets | 154 M |
| Long-Term Investments | 0 |
| PP&E | 11 M |
| Other Non-Current Assets | 143 M |
| Current Liabilities | 332 M |
| Accounts Payable | 35.2 M |
| Short-Term Debt | 2.14 M |
| Other Current Liabilities | 294 M |
| Non-Current Liabilities | 491 M |
| Long-Term Debt | 479 M |
| Other Non-Current Liabilities | 12.6 M |
EFFICIENCY
Earnings Waterfall
Coherus BioSciences, Inc.
| Revenue | 257 M |
| Cost Of Revenue | 163 M |
| Gross Profit | 94.5 M |
| Operating Expenses | 301 M |
| Operating Income | -203 M |
| Other Expenses | 34.7 M |
| Net Income | -238 M |
RATIOS
36.72%
GROSS MARGIN
-78.99%
OPERATING MARGIN
-92.48%
NET MARGIN
122.99%
ROE
-37.78%
ROA
-72.47%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Coherus BioSciences, Inc.
| Net Income | -238 M |
| Depreciation & Amortization | 3.79 M |
| Capital Expenditures | -286 K |
| Stock-Based Compensation | 43.1 M |
| Change in Working Capital | -36.8 M |
| Others | 190 M |
| Free Cash Flow | -175 M |
Wall Street Analysts Price Targets
Coherus BioSciences, Inc.
CHRS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Coherus BioSciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
450 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
11 months ago
Nov 22, 2023
|
Sell 450 K USD
|
Lanfear Dennis M
President & CEO |
- 223100
|
2.016 USD |
|
3 years ago
Oct 15, 2021
|
Sell 58.9 K USD
|
Stilwell McDavid
Chief Financial Officer |
- 3507
|
16.8003 USD |
|
3 years ago
Sep 27, 2021
|
Sell 1.81 M USD
|
HEALY JAMES
Director |
- 100150
|
18.06 USD |
|
3 years ago
Sep 28, 2021
|
Sell 830 K USD
|
HEALY JAMES
Director |
- 48329
|
17.17 USD |
|
3 years ago
Sep 29, 2021
|
Sell 4.61 M USD
|
HEALY JAMES
Director |
- 286076
|
16.12 USD |
|
3 years ago
Jun 09, 2021
|
Bought 49.7 K USD
|
Stilwell McDavid
Chief Financial Officer |
+ 3700
|
13.4237 USD |
|
3 years ago
Jun 08, 2021
|
Sell 421 K USD
|
Lanfear Dennis M
President & CEO |
- 31054
|
13.5644 USD |
|
3 years ago
Mar 09, 2021
|
Sell 1.86 M USD
|
Vexler Vladimir
Chief Scientific Officer |
- 114240
|
16.2488 USD |
|
3 years ago
Mar 05, 2021
|
Sell 314 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 20312
|
15.4635 USD |
|
3 years ago
Mar 05, 2021
|
Sell 98 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 6337
|
15.46 USD |
|
3 years ago
Feb 17, 2021
|
Sell 43.4 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2488
|
17.4511 USD |
|
3 years ago
Feb 01, 2021
|
Sell 160 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 7402
|
21.55 USD |
|
3 years ago
Jan 25, 2021
|
Sell 804 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 40000
|
20.1 USD |
|
3 years ago
Jan 25, 2021
|
Sell 117 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 6144
|
19 USD |
|
3 years ago
Jan 19, 2021
|
Sell 44.9 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
17.9408 USD |
|
3 years ago
Dec 17, 2020
|
Sell 43.8 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
17.512 USD |
|
3 years ago
Dec 10, 2020
|
Sell 318 K USD
|
Vexler Vladimir
Chief Scientific Officer |
- 17626
|
18.0453 USD |
|
3 years ago
Dec 09, 2020
|
Sell 903 K USD
|
Vexler Vladimir
Chief Scientific Officer |
- 49512
|
18.2397 USD |
|
3 years ago
Dec 07, 2020
|
Sell 162 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 8791
|
18.4161 USD |
|
3 years ago
Dec 03, 2020
|
Sell 929 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 49756
|
18.6727 USD |
|
3 years ago
Dec 04, 2020
|
Sell 924 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 49000
|
18.8509 USD |
|
4 years ago
Nov 17, 2020
|
Sell 43.7 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
17.4974 USD |
|
4 years ago
Nov 17, 2020
|
Sell 220 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 12420
|
17.6827 USD |
|
4 years ago
Nov 17, 2020
|
Sell 63.1 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 3567
|
17.677 USD |
|
4 years ago
Nov 18, 2020
|
Sell 77.1 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 4283
|
18 USD |
|
4 years ago
Nov 17, 2020
|
Sell 34.9 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 1995
|
17.4919 USD |
|
4 years ago
Oct 19, 2020
|
Sell 57.6 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 3217
|
17.8911 USD |
|
4 years ago
Oct 14, 2020
|
Sell 117 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 6144
|
19 USD |
|
4 years ago
Sep 17, 2020
|
Sell 94.2 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 5000
|
18.8432 USD |
|
4 years ago
Aug 17, 2020
|
Sell 96.9 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 5000
|
19.3702 USD |
|
4 years ago
Jul 17, 2020
|
Sell 274 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 15000
|
18.2458 USD |
|
4 years ago
Jun 22, 2020
|
Sell 967 K USD
|
Szela Mary T
Director |
- 54997
|
17.5784 USD |
|
4 years ago
Jun 17, 2020
|
Sell 43 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
17.22 USD |
|
4 years ago
Jun 17, 2020
|
Sell 3.43 M USD
|
Wahlstrom Mats
Director |
- 200000
|
17.1501 USD |
|
4 years ago
May 20, 2020
|
Sell 22.6 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 1278
|
17.66 USD |
|
4 years ago
May 18, 2020
|
Sell 42.9 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
17.17 USD |
|
4 years ago
Apr 17, 2020
|
Sell 77.8 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 5000
|
15.57 USD |
|
4 years ago
Apr 20, 2020
|
Sell 87.6 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 5150
|
17 USD |
|
4 years ago
Mar 03, 2020
|
Sell 2.29 M USD
|
Wahlstrom Mats
Director |
- 113844
|
20.0906 USD |
|
4 years ago
Mar 03, 2020
|
Sell 88.2 K USD
|
Wahlstrom Mats
Director |
- 4222
|
20.8941 USD |
|
4 years ago
Feb 19, 2020
|
Sell 70.6 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3159
|
22.3336 USD |
|
4 years ago
Feb 18, 2020
|
Sell 54.1 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
21.64 USD |
|
4 years ago
Feb 18, 2020
|
Sell 108 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 5000
|
21.638 USD |
|
4 years ago
Jan 17, 2020
|
Sell 48.9 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
19.5685 USD |
|
4 years ago
Jan 17, 2020
|
Sell 97.8 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 5000
|
19.5592 USD |
|
4 years ago
Jan 17, 2020
|
Sell 49.2 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
19.6853 USD |
|
4 years ago
Jan 15, 2020
|
Sell 69.2 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3520
|
19.6699 USD |
|
4 years ago
Jan 15, 2020
|
Sell 56.2 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 2798
|
20.0807 USD |
|
4 years ago
Dec 16, 2019
|
Sell 46.7 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
18.69 USD |
|
4 years ago
Nov 21, 2019
|
Sell 232 K USD
|
Lanfear Dennis M
President & CEO |
- 12500
|
18.5568 USD |
|
4 years ago
Nov 20, 2019
|
Sell 14.8 M USD
|
Lanfear Dennis M
President & CEO |
- 825000
|
18 USD |
|
4 years ago
Nov 20, 2019
|
Sell 61.9 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3159
|
19.5859 USD |
|
5 years ago
Nov 18, 2019
|
Sell 58.8 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3112
|
18.8809 USD |
|
5 years ago
Nov 14, 2019
|
Sell 48.2 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
19.26 USD |
|
5 years ago
Oct 18, 2019
|
Sell 26.4 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 1388
|
19.02 USD |
|
5 years ago
Oct 16, 2019
|
Sell 60 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3159
|
19 USD |
|
5 years ago
Oct 14, 2019
|
Sell 46 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
18.4 USD |
|
5 years ago
Sep 23, 2019
|
Sell 16.1 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 740
|
21.78 USD |
|
5 years ago
Sep 18, 2019
|
Sell 64.6 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3159
|
20.4368 USD |
|
5 years ago
Sep 16, 2019
|
Sell 50.1 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
20.03 USD |
|
5 years ago
Aug 21, 2019
|
Sell 5.39 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 260
|
20.7257 USD |
|
5 years ago
Aug 21, 2019
|
Sell 132 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 6058
|
21.7507 USD |
|
5 years ago
Aug 19, 2019
|
Sell 57.1 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3000
|
19.04 USD |
|
5 years ago
Aug 14, 2019
|
Sell 47.5 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
19 USD |
|
5 years ago
Jul 15, 2019
|
Sell 48 K USD
|
Anicetti Vincent R
Chief Operating Officer |
- 2500
|
19.2 USD |
|
5 years ago
Jun 28, 2019
|
Sell 4.41 M USD
|
HEALY JAMES
Director |
- 200000
|
22.05 USD |
|
5 years ago
Jul 02, 2019
|
Sell 3.62 M USD
|
HEALY JAMES
Director |
- 160000
|
22.61 USD |
|
5 years ago
Jun 20, 2019
|
Sell 6.78 M USD
|
HEALY JAMES
Director |
- 317130
|
21.37 USD |
|
5 years ago
Jun 18, 2019
|
Sell 57.9 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3000
|
19.3088 USD |
|
5 years ago
Jun 19, 2019
|
Sell 62.2 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3059
|
20.3224 USD |
|
5 years ago
Jun 19, 2019
|
Sell 2.08 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 100
|
20.81 USD |
|
5 years ago
Jun 19, 2019
|
Sell 13.3 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 667
|
20 USD |
|
5 years ago
May 30, 2019
|
Sell 631 K USD
|
Lanfear Dennis M
President & CEO |
- 32398
|
19.4852 USD |
|
5 years ago
May 22, 2019
|
Sell 5.34 M USD
|
HEALY JAMES
Director |
- 257870
|
20.69 USD |
|
5 years ago
Mar 20, 2019
|
Sell 44.8 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3000
|
14.9207 USD |
|
6 years ago
Sep 10, 2018
|
Sell 32.7 K USD
|
FINCK BARBARA K
Chief Medical Officer |
- 1760
|
18.5789 USD |
|
6 years ago
Aug 29, 2018
|
Sell 512 K USD
|
HEALY JAMES
Director |
- 25000
|
20.5 USD |
|
6 years ago
Aug 13, 2018
|
Sell 33.5 K USD
|
FINCK BARBARA K
Chief Medical Officer |
- 1760
|
19.0227 USD |
|
6 years ago
Jul 23, 2018
|
Sell 172 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 9291
|
18.5633 USD |
|
6 years ago
Jul 10, 2018
|
Sell 18.9 K USD
|
FINCK BARBARA K
Chief Medical Officer |
- 1260
|
15 USD |
|
6 years ago
Jul 09, 2018
|
Sell 7.52 K USD
|
FINCK BARBARA K
Chief Medical Officer |
- 500
|
15.03 USD |
|
6 years ago
Jun 18, 2018
|
Sell 26.4 K USD
|
FINCK BARBARA K
Chief Medical Officer |
- 1760
|
15 USD |
|
6 years ago
May 16, 2018
|
Sell 341 K USD
|
Lanfear Dennis M
See Remarks |
- 20984
|
16.2631 USD |
|
7 years ago
Aug 08, 2017
|
Sell 263 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 17535
|
15.0157 USD |
|
7 years ago
Jul 05, 2017
|
Sell 9 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 600
|
15 USD |
|
7 years ago
Jun 01, 2017
|
Sell 194 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 9601
|
20.201 USD |
|
7 years ago
Jun 01, 2017
|
Sell 36.3 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 1732
|
20.9827 USD |
|
7 years ago
May 01, 2017
|
Sell 227 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 11333
|
19.997 USD |
|
7 years ago
Apr 03, 2017
|
Sell 235 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 11333
|
20.7346 USD |
|
7 years ago
Mar 01, 2017
|
Sell 274 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 11333
|
24.1923 USD |
|
7 years ago
Feb 01, 2017
|
Sell 310 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 11333
|
27.3674 USD |
|
7 years ago
Jan 25, 2017
|
Sell 105 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3900
|
27 USD |
|
7 years ago
Jan 03, 2017
|
Sell 297 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 10650
|
27.9048 USD |
|
7 years ago
Jan 03, 2017
|
Sell 19.5 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 683
|
28.6037 USD |
|
7 years ago
Dec 16, 2016
|
Sell 110 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3900
|
28.2987 USD |
|
7 years ago
Dec 07, 2016
|
Sell 203 K USD
|
Wahlstrom Mats
Director |
- 7393
|
27.503 USD |
|
7 years ago
Dec 08, 2016
|
Sell 1.27 M USD
|
Wahlstrom Mats
Director |
- 46190
|
27.5243 USD |
|
7 years ago
Dec 01, 2016
|
Sell 86.4 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 3200
|
27.0141 USD |
|
7 years ago
Dec 01, 2016
|
Sell 224 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 8133
|
27.5517 USD |
|
8 years ago
Nov 18, 2016
|
Sell 110 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3900
|
28.1936 USD |
|
8 years ago
Nov 01, 2016
|
Sell 312 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 11333
|
27.5339 USD |
|
8 years ago
Oct 21, 2016
|
Sell 119 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3900
|
30.6161 USD |
|
8 years ago
Oct 03, 2016
|
Sell 206 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 8096
|
25.4698 USD |
|
8 years ago
Oct 03, 2016
|
Sell 85 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 3237
|
26.2582 USD |
|
8 years ago
Sep 26, 2016
|
Sell 117 K USD
|
Viret Jean-Frederic
Chief Financial Officer |
- 3900
|
29.8846 USD |
|
8 years ago
Sep 20, 2016
|
Sell 127 K USD
|
Lanfear Dennis M
President and CEO |
- 4010
|
31.7512 USD |
|
8 years ago
Sep 21, 2016
|
Sell 1.59 K USD
|
Lanfear Dennis M
President and CEO |
- 50
|
31.75 USD |
|
8 years ago
Sep 16, 2016
|
Sell 92.2 K USD
|
Lanfear Dennis M
President and CEO |
- 2900
|
31.7928 USD |
|
8 years ago
Sep 01, 2016
|
Sell 510 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 16999
|
29.985 USD |
|
8 years ago
Aug 08, 2016
|
Sell 469 K USD
|
Watler Peter K.
Chief Technical Officer |
- 15621
|
30.0012 USD |
|
8 years ago
Aug 08, 2016
|
Sell 1.2 M USD
|
Watler Peter K.
Chief Technical Officer |
- 40000
|
30.0004 USD |
|
8 years ago
Aug 08, 2016
|
Sell 14.2 K USD
|
FMR LLC
|
- 475
|
29.89 USD |
|
8 years ago
Aug 08, 2016
|
Sell 62.8 K USD
|
FMR LLC
|
- 2100
|
29.89 USD |
|
8 years ago
Aug 08, 2016
|
Sell 32.9 K USD
|
FMR LLC
|
- 1100
|
29.92 USD |
|
8 years ago
Aug 08, 2016
|
Sell 40.3 K USD
|
FMR LLC
|
- 1349
|
29.84 USD |
|
8 years ago
Aug 08, 2016
|
Sell 2.54 M USD
|
FMR LLC
|
- 84976
|
29.86 USD |
|
8 years ago
Aug 08, 2016
|
Sell 299 K USD
|
FMR LLC
|
- 10000
|
29.87 USD |
|
8 years ago
Aug 04, 2016
|
Sell 653 K USD
|
FMR LLC
10 percent owner |
- 23200
|
28.16 USD |
|
8 years ago
Aug 04, 2016
|
Sell 5.59 K USD
|
FMR LLC
10 percent owner |
- 200
|
27.97 USD |
|
8 years ago
Aug 04, 2016
|
Sell 2.79 K USD
|
FMR LLC
10 percent owner |
- 100
|
27.87 USD |
|
8 years ago
Aug 04, 2016
|
Sell 2.8 K USD
|
FMR LLC
10 percent owner |
- 100
|
27.95 USD |
|
8 years ago
Aug 05, 2016
|
Sell 720 K USD
|
FMR LLC
10 percent owner |
- 25000
|
28.78 USD |
|
8 years ago
Aug 01, 2016
|
Sell 289 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 11333
|
25.539 USD |
|
8 years ago
Jul 21, 2016
|
Sell 85.7 K USD
|
Watler Peter K.
Chief Technical Officer |
- 3291
|
26.0513 USD |
|
8 years ago
Jul 21, 2016
|
Sell 18.5 K USD
|
Watler Peter K.
Chief Technical Officer |
- 700
|
26.4814 USD |
|
8 years ago
Jul 20, 2016
|
Sell 1.25 M USD
|
Watler Peter K.
Chief Technical Officer |
- 50000
|
25.0242 USD |
|
8 years ago
Jul 20, 2016
|
Sell 594 K USD
|
Watler Peter K.
Chief Technical Officer |
- 23741
|
25 USD |
|
8 years ago
Jul 11, 2016
|
Sell 871 K USD
|
Watler Peter K.
Chief Technical Officer |
- 43495
|
20.0237 USD |
|
8 years ago
Jul 01, 2016
|
Sell 71.8 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 4250
|
16.8882 USD |
|
8 years ago
Jun 01, 2016
|
Sell 79.4 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 4250
|
18.6729 USD |
|
8 years ago
Feb 29, 2016
|
Bought 0 USD
|
Wahlstrom Mats
Director |
+ 1000000
|
0 USD |
|
9 years ago
Aug 18, 2015
|
Sell 213 K USD
|
Wahlstrom Mats
Director |
- 6372
|
33.502 USD |
|
8 years ago
May 17, 2016
|
Sell 240 K USD
|
Watler Peter K.
Chief Technical Officer |
- 12000
|
20 USD |
|
8 years ago
May 02, 2016
|
Sell 29.9 K USD
|
Watler Peter K.
Chief Technical Officer |
- 1493
|
20 USD |
|
9 years ago
Nov 20, 2015
|
Sell 548 K USD
|
Watler Peter K.
Chief Technical Officer |
- 20000
|
27.4089 USD |
|
8 years ago
May 02, 2016
|
Sell 70.8 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 3698
|
19.1329 USD |
|
8 years ago
May 02, 2016
|
Sell 10.8 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 552
|
19.6346 USD |
|
8 years ago
Apr 01, 2016
|
Sell 69.4 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 3273
|
21.1974 USD |
|
8 years ago
Apr 01, 2016
|
Sell 21.4 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 977
|
21.8871 USD |
|
8 years ago
Feb 29, 2016
|
Bought 0 USD
|
Wahlstrom Mats
Director |
+ 0
|
0 USD |
|
8 years ago
Feb 29, 2016
|
Bought 0 USD
|
Troendle August J.
Director |
+ 0
|
0 USD |
|
8 years ago
Mar 01, 2016
|
Sell 7.28 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 485
|
15.0026 USD |
|
8 years ago
Mar 02, 2016
|
Sell 92.1 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 6015
|
15.3152 USD |
|
8 years ago
Feb 05, 2016
|
Sell 30 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 2000
|
15.0202 USD |
|
8 years ago
Jan 04, 2016
|
Sell 84.5 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 3950
|
21.4038 USD |
|
8 years ago
Jan 04, 2016
|
Sell 6.71 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 300
|
22.3567 USD |
|
8 years ago
Dec 01, 2015
|
Sell 69.1 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 2400
|
28.8017 USD |
|
8 years ago
Dec 01, 2015
|
Sell 265 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 8933
|
29.6734 USD |
|
8 years ago
Nov 30, 2015
|
Sell 12.7 K USD
|
Lanfear Dennis M
President and CEO |
- 400
|
31.75 USD |
|
9 years ago
Nov 12, 2015
|
Sell 81.7 K USD
|
Richards Christos
Director |
- 3000
|
27.2309 USD |
|
9 years ago
Nov 13, 2015
|
Sell 219 K USD
|
Richards Christos
Director |
- 7988
|
27.3762 USD |
|
9 years ago
Nov 13, 2015
|
Sell 112 K USD
|
Richards Christos
Director |
- 4012
|
27.929 USD |
|
9 years ago
Nov 02, 2015
|
Sell 473 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 16516
|
28.6457 USD |
|
9 years ago
Nov 02, 2015
|
Sell 55.6 K USD
|
Herman Alan C.
Chief Scientific Officer |
- 1900
|
29.2508 USD |
7. News
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
seekingalpha.com
- 1 week ago
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.27 per share a year ago.
zacks.com
- 1 week ago
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA ® net revenue, quarter-over-quarter –
globenewswire.com
- 1 week ago
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
globenewswire.com
- 2 weeks ago
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief Executive Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer Bryan McMichael - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Billal Jahangiri - Truist Securities Michael Nedelcovych - TD Cowen Colleen Kusy - Robert W.
seekingalpha.com
- 3 months ago
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.38 per share a year ago.
zacks.com
- 3 months ago
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
globenewswire.com
- 3 months ago
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology –
globenewswire.com
- 4 months ago
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024.
globenewswire.com
- 5 months ago
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors
globenewswire.com
- 5 months ago
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until June 26, 2024.
globenewswire.com
- 5 months ago
Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Denny Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer Rosh Dias - Chief Medical Officer Theresa LaVallee - Chief Development Officer Bryan McMichael - Interim Chief Financial Officer Conference Call Participants Michael Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Colleen Kusy - Baird Operator Ladies and gentlemen, thank you for standing by.
seekingalpha.com
- 6 months ago
8. Profile Summary
Coherus BioSciences, Inc. CHRS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 85.7 M
Dividend Yield
0.00%
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Contact
333 Twin Dolphin Drive, Redwood City, CA, 94065
https://www.coherus.com
IPO Date
Nov. 6, 2014
Employees
235
Officers
Mr. Michael Chen
Senior Vice President of Commercial Analytics & Trade
Ms. Rebecca Sunshine
Chief Human Resources Officer
Mr. Cheston Turbyfill
Vice President of Communications
Mr. Dennis M. Lanfear
Chairman, President & Chief Executive Officer
Ms. Jami Taylor
Vice President of Investor Relations
Mr. Bryan J. McMichael
Former Interim Chief Financial Officer, Principal Financial and Acc. Off., SVice President-Acc. & Corporate Controller
Mr. Paul Reider
Chief Commercial Officer
Mr. Scott Saywell
Executive Vice President of Corporate Development
Mr. Andy Rittenberg
Executive Vice President of General Counsel
Mr. Richard L. Hameister
Chief Technical Officer